目的：非小细胞肺癌(non-small-cell lung cancer,NSCLC)术后化疗耐药成为治疗失败的主要原因,此项研究的目的为探索在接受以铂类为基础的辅助化疗的非小细胞肺癌(NSCLC)患者中,乳腺癌和卵巢癌易感基因1(The breast and ovarian cancer susceptibility gene1,BRCA1)mRNA的表达及其临床预后意义。方法：采用逆转录-聚合酶链反应(RT-PCR)方法检测85例肿瘤组织以及其中34例癌旁组织中ERCC1基因mRNA的表达。回顾性分析基因与患者使用化疗后在无进展生存期(PFS)和总生存期(OS)之间的关系。结果：BRCA1在癌及癌旁组织中的表达分别为16.5%和44.1%(P=0.002),BRCA1阴性表达的患者相比较阳性表达的来说有着更长的PFS (P=0.088)和OS(P=0.057),但没有统计学意义。结论：随着样本量的增大以及随访时间的延长,BRCA1 mRNA很可能成为预测非小细胞肺癌手术后生存决定性的指标之一。%Objective:The aim of this study was to investigate prognostic value of the breast and ovarian cancer susceptibility gene1 (BRCA1) in patients with non-small cell lung cancer (NSCLC).Methods:Messenger RNA expressions of gene was examined in 85 tumor tissues and 34 adjacent tissue samples using semi-quantitative RT-PCR.The expression of gene was analyzed in relation to progression-free survival (PFS) and overall survival (OS).Results:The expressions of BRCA1 in tumor and adjacent tissues were 16.5%and 44.1%(P=0.002). Patients with BRCA1 negative expression had a significantly longer PFS (P=0.088) and OS (P=0.057) than those with positive expression, however,there was no statistical significance.Conclusion:BRCA1 mRNA could be one of the markers used to predict the prognosis of NSCLC accompanied by enlarging study samples and extending the follow-up time.
展开▼
